Αρχική World News Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients with... World News Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients with MSI-H or dMMR mCRC Από Ogkologos - 9 Δεκεμβρίου, 2024 936 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube,... 25 Φεβρουαρίου, 2026 NICE recommends pembrolizumab for 1,600 more people with breast cancer 14 Νοεμβρίου, 2022 Does Sugar Cause Cancer? 9 Νοεμβρίου, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Nadofaragene Firadenovec 24 Απριλίου, 2026 Φόρτωση περισσοτέρων HOT NEWS EMA Recommends Granting a Marketing Authorisation for Lutetium (177lu) Chloride Breast Cancer Patient Fights To Have Mastectomy During COVID-19 Restrictions And... Coping with Grief: An Interview with Author Rebecca Munn ESMO Breast Cancer 2025, Munich, Germany, 14-17 May 2025